<code id='EADF58DB49'></code><style id='EADF58DB49'></style>
      • <acronym id='EADF58DB49'></acronym>
      <center id='EADF58DB49'><center id='EADF58DB49'><tfoot id='EADF58DB49'></tfoot></center><abbr id='EADF58DB49'><dir id='EADF58DB49'><tfoot id='EADF58DB49'></tfoot><noframes id='EADF58DB49'>
      • <optgroup id='EADF58DB49'><strike id='EADF58DB49'><sup id='EADF58DB49'></sup></strike><code id='EADF58DB49'></code></optgroup>
        5. <b id='EADF58DB49'><label id='EADF58DB49'><select id='EADF58DB49'><dt id='EADF58DB49'><span id='EADF58DB49'></span></dt></select></label></b><u id='EADF58DB49'></u>
          <i id='EADF58DB49'><strike id='EADF58DB49'><tt id='EADF58DB49'><pre id='EADF58DB49'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / Wikipedia / explore      
           
     
           
      
          explore 
           
      
           
      
           
       2025-09-29 22:36:11 
   
      
           
      
           
                        
          explore  
          
                                   
                 
                                      author：knowledge   
                                        
                                      
                                      Page View：57
                                  
                                    
          
                                   
          Rachel Haurwitz of Caribou Biosciences
          Rachel Haurwitz, CEO of Caribou Biosciences.																									Elizabeth D. Herman for STAT
          Caribou Biosciences said Thursday that its off-the-shelf CAR-T therapy induced durable, complete remissions in patients with advanced B-cell lymphoma that move it closer to the benchmarks set by more established, patient-specific CAR-T therapies.
          In an update to an early-stage study, 44% of the 16 patients treated with Caribou’s on-demand therapy, called CB-010, achieved a complete remission lasting a minimum of six months — a key threshold of durability.
          advertisement
          The CB-010 result is still preliminary, but it begins to compare favorably to currently approved CAR-T therapies, which must be custom made for each patient and have shown durable remission rates in the range of 36-40%, said Caribou CEO Rachel Haurwitz.
          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!					
          GET STARTED													Log In											
                      
                              
          
                                 Previous article：

                                
                                          3 questions for the future of Biden's cancer moonshot
                                
                            
          Next article：  
                                      
                                          Apple is now the first public company to be valued at $3 trillion
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles